Document is current
Any future updates will be listed below
-
Authors
Natoli, Valentina
Palmeri, Serena
Rebollo-Giménez, Ana Isabel
Matucci-Cerinic, Caterina
Bocca, Paola
Caorsi, Roberta
Volpi, Stefano
Papa, Riccardo
Consolaro, Alessandro
Gattorno, Marco
Ravelli, Angelo
Rosina, Silvia https://orcid.org/0000-0002-3667-6155
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 2 December 2024
First Online: 25 February 2025
Declarations
:
: The off-label use of tofacitinib was approved by the local ethics committee (“Comitato Buon Uso del Farmaco”) of the IRRCS Giannina Gaslini.
: Written informed consent for publication of their clinical details and/or clinical images was obtained from the parent of the patient. A copy of the consent form is available for review by the Editor of this journal.
: VN, SP, AIRG, PB, SR have no competing interests. CMC, SV and RP received speaker fee from SOBI. RC received speaker fee from Sobi and Novartis, consultancy from SOBI, Novartis and Eli Lilly. AC received research support from Pfizer and speaker fee from Novartis. MG received speaker fee and consultancy from SOBI and Novartis. AR received consultancy and speaker fee from Abbvie, Alexion, Alfasigma, Angelini, BMS, Galapagos, Novartis, Pfizer, Reckitt-Benckiser, Roche, SOBI, research support from Novartis, Pfizer.
